These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29698188)

  • 1. How Data Packages Lacking Phase III Pivotal Trial Data Can Support Regulatory Approval and Reimbursement for Oncologics in Australia.
    Macaulay R; Siddiqui MK; Stoddart S
    Value Health Reg Issues; 2015 May; 6():143-149. PubMed ID: 29698188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.
    Phan YHL; De Abreu Lourenco R; Haas M; van der Linden N
    Mult Scler Relat Disord; 2018 Oct; 25():144-149. PubMed ID: 30077086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delays in access to affordable medicines: putting policy into perspective.
    Pearce A; van Gool K; Haywood P; Haas M
    Aust Health Rev; 2012 Nov; 36(4):412-8. PubMed ID: 23062753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review.
    Lingaratnam S; Hussainy SY; Murphy A; Perrin C; Samuvel M; Mehrvarz E; Lim CX; Zalcberg J
    J Pharm Policy Pract; 2024; 17(1):2389120. PubMed ID: 39175661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
    Pham C; Le K; Draves M; Seoane-Vazquez E
    JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
    George B; Harris A; Mitchell A
    Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
    Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
    Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
    Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
    JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
    Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
    BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
    [No Abstract]   [Full Text] [Related]  

  • 19. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.